In a phase 3 trial of Ocrevus (ocrelizumab), Roche Group’s Genentech saw its twice-yearly subcutaneous injection meet primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS, according to a news release.
The investigative subcutaneous therapy had similar safety and efficacy results as its approved intravenous solution, according to Genentech.
“Detailed results from the trial will be presented at an upcoming medical meeting and submitted to health authorities around the world,” the company said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
